On November 20, 2023, Fulcrum Therapeutics Inc (NASDAQ: FULC) opened at $4.15, higher 12.05% from the last session. During the day, the shares moved up to $4.69 and dropped to $4.15 before settling in for the closing price of $4.15. Price fluctuations for FULC have ranged from $2.25 to $15.00 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 10.06%. Company’s average yearly earnings per share was noted 32.79% at the time writing. With a float of $58.13 million, this company’s outstanding shares have now reached $61.82 million.
The extent of productivity of a business whose workforce counts for 89 workers is very important to gauge. In terms of profitability, gross margin is +61.94, operating margin of -1768.12, and the pretax margin is -1732.43.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Fulcrum Therapeutics Inc is 5.98%, while institutional ownership is 87.73%. The most recent insider transaction that took place on May 10, was worth 695. In this transaction Principal Accounting Officer of this company sold 210 shares at a rate of $3.31, taking the stock ownership to the 15,992 shares. Before that another transaction happened on Jan 20, when Company’s 10% Owner bought 1,923,076 for $13.00, making the entire transaction worth $24,999,988. This insider now owns 11,609,704 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$0.39 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.43) by $0.04. This company achieved a net margin of -1732.43 while generating a return on equity of -53.53. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.40% during the next five years compared to -17.57% drop over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Check out the current performance indicators for Fulcrum Therapeutics Inc (FULC). In the past quarter, the stock posted a quick ratio of 18.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 109.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.69, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.80 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
The latest stats from [Fulcrum Therapeutics Inc, FULC] show that its last 5-days average volume of 0.55 million was inferior to 1.28 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 71.16%. Additionally, its Average True Range was 0.36.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 46.32%, which indicates a significant decrease from 97.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 148.85% in the past 14 days, which was higher than the 101.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.99, while its 200-day Moving Average is $4.37. Now, the first resistance to watch is $4.84. This is followed by the second major resistance level at $5.04. The third major resistance level sits at $5.38. If the price goes on to break the first support level at $4.30, it is likely to go to the next support level at $3.96. The third support level lies at $3.76 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
There are currently 61,823K shares outstanding in the company with a market cap of 287.46 million. Presently, the company’s annual sales total 6,340 K according to its annual income of -109,870 K. Last quarter, the company’s sales amounted to 760 K and its income totaled -24,020 K.